Ivan Urits

Dr. Ivan Urits

Southcoast Health, Southcoast Health Physicians Group Pain Medicine, Wareham, MA, USA; Louisiana State University Shreveport Health, Department of Anesthesiology and Pain Medicine, Shreveport, LA, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2019 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
IUIvan Urits
Ivan Urits
ABAaron Burshtein
Aaron Burshtein
MSMedha Sharma
Medha Sharma
LTLauren Testa
Lauren Testa
PGPeter A. Gold
Peter A. Gold
AKAlan D. Kaye
Alan D. Kaye

5 August 2021 in Neurology International
Verified
Journal Article
Open access
PDF file
AEAmber Edinoff
Amber Edinoff
HAHaseeb Akuly
Haseeb Akuly
THTony A. Hanna
Tony A. Hanna
COCarolina O. Ochoa
Carolina O. Ochoa
SPShelby J. Patti
Shelby J. Patti
Adam KayeAdam Kaye
Adam Kaye
Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manage due to many factors. Beginning with the introduction of fluoxetine to the United States in 1988, selective serotonin reuptake inhibitors (SSRIs) quickly became a mainstay of treatment for a variety of psychiatric disorders. The primary mechanism of action of SSRIs is to inhibit presynaptic reuptake of serotonin at the serotonin transporter, subsequently increasing serotonin at the postsynaptic membrane in the serotonergic synapse. The six major SSRIs that are marketed in the USA today, fluoxetine, citalopram, escitalopram, paroxetine, sertraline, and fluvoxamine, are a group of structurally unrelated molecules that share a similar mechanism of action. While their primary mechanism of action is similar, each SSRI has unique pharmacokinetics, pharmacodynamics, and side effect profile. One of the more controversial adverse effects of SSRIs is the black box warning for increased risk of suicidality in children and young adults aged 18–24. There is a lack of understanding of the complexities and interactions between SSRIs in the developing brain of a young person with depression. Adults, who do not have certain risk factors, which could be confounding factors, do not seem to carry this increased risk of suicidality. Ultimately, when prescribing SSRIs to any patient, a risk–benefit analysis must factor in the potential treatment effects, adverse effects, and dangers of the illness to be treated. The aim of this review is to educate clinicians on potential adverse effects of SSRIs.

12 August 2020 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
IUIvan Urits
Ivan Urits
DSDaniel Swanson
Daniel Swanson
MSMichael C. Swett
Michael C. Swett
APAnjana Patel
Anjana Patel
KBKevin Berardino
Kevin Berardino
OVOmar Viswanath
Omar Viswanath
Hereditary variant transthyretin amyloidosis (ATTRv) is a rare genetic defect that affects about 5000–10,000 people worldwide, causing amyloidosis secondary to misfolding of mutant transthyretin (TTR) protein fibrils. TTR mutations can cause protein deposits in many extracellular regions of organs, but those deposits in cardiac and axonal cells are the primary cause of this clinical syndrome. Treatment options are limited, but new drugs are being developed. Patisiran, a novel drug, is a liposomal siRNA against TTR that specifically targets this protein, reducing the accumulation of TTR in tissues, with subsequent improvement in both neuropathy and cardiac function. Patisiran is likely to serve as a prototype for the development of further intelligent drug solutions for use in targeted therapy. In this review we summarize the evidence currently available on the treatment of polyneuropathy in people with ATTRv with patisiran. We review the evidence on its efficacy, safety, and indications of use, citing novel and seminal papers on these subjects.

6 August 2019 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
MJMark R. Jones
Mark R. Jones
IUIvan Urits
Ivan Urits
KEKen P. Ehrhardt
Ken P. Ehrhardt
JCJohn N. Cefalu
John N. Cefalu
JKJulia B. Kendrick
Julia B. Kendrick
OVOmar Viswanath
Omar Viswanath

4 March 2020 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
ACAlexander Capuco
Alexander Capuco
IUIvan Urits
Ivan Urits
JHJamal Hasoon
Jamal Hasoon
RCRebecca Chun
Rebecca Chun
BGBrittany Gerald
Brittany Gerald
OVOmar Viswanath
Omar Viswanath
The human gut microbiome partakes in a bidirectional communication pathway with the central nervous system (CNS), named the microbiota–gut–brain axis. The microbiota–gut–brain axis is believed to modulate various central processes through the vagus nerve as well as production of microbial metabolites and immune mediators which trigger changes in neurotransmission, neuroinflammation, and behavior. Little is understood about the utilization of microbiome manipulation to treat disease. Though studies exploring the role of the microbiome in various disease processes have shown promise, mechanisms remain unclear and evidence-based treatments for most illnesses have not yet been developed. The animal studies reviewed here offer an excellent array of basic science research that continues to clarify mechanisms by which the microbiome may affect mental health. More evidence is needed, particularly as it relates to translating this work to human subjects. The studies presented in this paper largely demonstrate encouraging results in the treatment of depression. Limitations include small sample sizes and heterogeneous methodology. The exact mechanism by which the gut microbiota causes or alters neuropsychiatric disease states is not fully understood. In this review, we focus on recent studies investigating the relationship between gut microbiome dysbiosis and the pathogenesis of depression. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

29 January 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ADAllison Desforges
Allison Desforges
CHChance M. Hebert
Chance M. Hebert
ASAllyson L. Spence
Allyson L. Spence
BRBailey Reid
Bailey Reid
HDHEMANGINI A DHAIBAR
HEMANGINI A DHAIBAR
OVOmar Viswanath
Omar Viswanath
When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory rather than motor and include reduced feeling and heightened sensitivity to pressure, pain, temperature, and touch. The pathophysiology of CIPN is very complex, and it involves multiple mechanisms leading to its development which will be described specifically for each chemotherapeutic class. There are currently no approved or effective agents for CIPN prevention, and Duloxetine is the only medication that is an effective treatment against CIPN. There is an unavoidable necessity to develop preventative and treatment approaches for CIPN due to its detrimental impact on patients' lives. The purpose of this review is to examine CIPN, innovative pharmacological and nonpharmacological therapy and preventive strategies for this illness, and future perspectives for this condition and its therapies.